US2004176450A1PendingUtilityA1
Formoterol tartrate polymorph
Est. expiryNov 9, 2021(expired)· nominal 20-yr term from priority
A61P 9/00A61P 9/08A61P 11/08C07C 231/24C07B 2200/13C07C 233/25A61K 31/205
60
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of preparation of a highly pure salt of R,R-formoterol L-tartrate is disclosed. The process provides the most thermodynamically stable polymorph by recrystallization of a novel polymorph.
Claims
exact text as granted — not AI-modified1 . A crystalline solid consisting of greater than 99.5% by weight of (R,R)-formoterol L-tartrate and less than 0.5% by weight of chemical impurities other than formoterol L-tartrate; said chemical impurities including less than 0.2% by weight (based on total crystalline solid) of a compound of formula 7
said (R,R)-formoterol L-tartrate being at least 95% in the polymorphic form of a thermodynamically stable third polymorph (a) having peaks at the diffraction degrees with the intensity shown below in an x-ray powder diffraction pattern:
peak number
2-Theta
Intensity
1
8.8
33.1
2
9.3
33.4
3
12.1
58.1
4
12.4
60.6
5
14.2
30.9
6
15.2
87.4
7
15.5
82.8
8
16.8
69.8
9
18.9
39.6
10
19.7
41.1
11
20.8
40.6
12
22.5
38.8
13
23.0
59.9
14
23.7
100.0
15
25.6
55.9
16
26.8
37.2
17
28.6
25.6
18
30.9
37.2
19
36.1
28.0
20
38.1
25.0
21
39.1
22.7
22
41.5
21.3
23
43.3
20.9
2 . A method for for preventing bronchoconstriction or inducing bronchodilation in a mammal comprising administering to said mammal a therapeutically effective amount of the solid R,R-formoterol L-(+)-tartrate of claim 1 .
3 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the solid R,R-formoterol L-(+)-tartrate of claim 1 .
4 . An aerosol pharmaceutical composition according to claim 3 .
5 . An oral pharmaceutical composition according to claim 3 .
6 . An oral pharmaceutical composition according to claim 5 in the form of a tablet, capsule or syrup.
7 . A dry powder pharmaceutical composition for inhalation according to claim 4 .
8 . A crystalline solid consisting of greater than 99.5% by weight of (R,R)-formoterol L-tartrate and less than 0.5% by weight of chemical impurities other than formoterol L-tartrate; said chemical impurities including less than 0.1% by weight (based on total crystalline solid) of a compound of formula 8
said (R,R)-formoterol L-tartrate being at least 95% in the polymorphic form of a thermodynamically stable third polymorph (A) having peaks at the diffraction degrees with the intensity shown below in an X-ray powder diffraction pattern:
peak number
2-Theta
Intensity
1
8.8
33.1
2
9.3
33.4
3
12.1
58.1
4
12.4
60.6
5
14.2
30.9
6
15.2
87.4
7
15.5
82.8
8
16.8
69.8
9
18.9
39.6
10
19.7
41.1
11
20.8
40.6
12
22.5
38.8
13
23.0
59.9
14
23.7
100.0
15
25.6
55.9
16
26.8
37.2
17
28.6
25.6
18
30.9
37.2
19
36.1
28.0
20
38.1
25.0
21
39.1
22.7
22
41.5
21.3
23
43.3
20.9
9 . A crystalline solid according to claim 8 , consisting of greater than 99.5% by weight of (R,R)-formoterol L-tartrate and less than 0.5% by weight of chemical impurities other than formoterol L-tartrate; said chemical impurities including 0.05% by weight (based on total crystalline solid) or less of a compound of formula 8.
10 . A method for preventing bronchoconstriction or inducing bronchodilation in a mammal comprising administering to said mammal a therapeutically effective amount of the solid R,R-formoterol L-(+)-tartrate of claim 8 .
11 . A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the solid R,R-formoterol L-(+)-tartrate of claim 8 .
12 . An aerosol pharmaceutical composition according to claim 10 .
13 . An oral pharmaceutical composition according to claim 10 .
14 . An oral pharmaceutical composition according to claim 12 in the form of a tablet, capsule or syrup.
15 . A dry powder pharmaceutical composition for inhalation according to claim 10.Join the waitlist — get patent alerts
Track US2004176450A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.